Drug Response Phenotype Terms

Yiqing Zhao,Matthew Brush,Chen Wang,Alex H. Wagner,Hongfang Liu,Robert R. Freimuth

DOI: https://doi.org/10.5281/zenodo.7186983

2022-01-01

Abstract:Data and code for "Leveraging a Pharmacogenomics Knowledge-base to Formulate a Drug Response Phenotype Terminology for Genomic Medicine" published in Bioinformatics

What problem does this paper attempt to address?

Leveraging a pharmacogenomics knowledgebase to formulate a drug response phenotype terminology for genomic medicine

Yiqing Zhao,Matthew Brush,Chen Wang,Alex H Wagner,Hongfang Liu,Robert R Freimuth

DOI: https://doi.org/10.1093/bioinformatics/btac646

IF: 5.8

2022-10-12

Bioinformatics

Abstract:Abstract Motivation Despite the increasing evidence of utility of genomic medicine in clinical practice, systematically integrating genomic medicine information and knowledge into clinical systems with a high-level of consistency, scalability and computability remains challenging. A comprehensive terminology is required for relevant concepts and the associated knowledge model for representing relationships. In this study, we leveraged PharmGKB, a comprehensive pharmacogenomics (PGx) knowledgebase, to formulate a terminology for drug response phenotypes that can represent relationships between genetic variants and treatments. We evaluated coverage of the terminology through manual review of a randomly selected subset of 200 sentences extracted from genetic reports that contained concepts for ‘Genes and Gene Products’ and ‘Treatments’. Results Results showed that our proposed drug response phenotype terminology could cover 96% of the drug response phenotypes in genetic reports. Among 18 653 sentences that contained both ‘Genes and Gene Products’ and ‘Treatments’, 3011 sentences were able to be mapped to a drug response phenotype in our proposed terminology, among which the most discussed drug response phenotypes were response (994), sensitivity (829) and survival (332). In addition, we were able to re-analyze genetic report context incorporating the proposed terminology and enrich our previously proposed PGx knowledge model to reveal relationships between genetic variants and treatments. In conclusion, we proposed a drug response phenotype terminology that enhanced structured knowledge representation of genomic medicine. Supplementary information Supplementary data are available at Bioinformatics online.

biochemical research methods,biotechnology & applied microbiology,mathematical & computational biology
Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421114.v1

2023-01-01

Abstract:Analysis of drug response predicting biomarkers in PDXE dataset. For each tissue type and drug, association between genomic features (mutation copy number variation and gene expression) and drug response in PDXs are reported.
A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Zhiwei Liu,Shangwen Jiang,Bingbing Hao,Shuyu Xie,Yingluo Liu,Yuqi Huang,Heng Xu,Cheng Luo,Min Huang,Minjia Tan,Jun-Yu Xu

DOI: https://doi.org/10.1016/j.jpha.2023.08.021

IF: 14.026

2024-01-01

Journal of Pharmaceutical Analysis

Abstract:Pharmacological perturbation studies based on protein-level signatures are fundamental for drug discovery. In the present study, we used a mass spectrometry (MS)-based proteomic platform to profile the whole proteome of the breast cancer MCF7 cell line under stress induced by 78 bioactive compounds. The integrated analysis of perturbed signal abundance revealed the connectivity between phenotypic behaviors and molecular features in cancer cells. Our data showed functional relevance in exploring the novel pharmacological activity of phenolic xanthohumol, as well as the noncanonical targets of clinically approved tamoxifen, lovastatin, and their derivatives. Furthermore, the rational design of synergistic inhibition using a combination of histone methyltransferase and topoisomerase was identified based on their complementary drug fingerprints. This study provides rich resources for the proteomic landscape of drug responses for precision therapeutic medicine.
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind Singh Mer,Wail Ba-alawi,Petr Smirnov,Yi Xiao Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1101/471227

IF: 11.2

2019-01-01

Cancer Research

Abstract:AbstractIdentifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology.Significance:A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX.See related commentary by Meehan, p. 4324
Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421111.v1

2023-01-01

Abstract:Association between drug class and pathways in PDXs. Drugs have been classified into categories according to their known target and association is computed using gene set enrichment analysis.
Internet Resources Related to Drug Action and Human Response: A Review

L. X. Yao,Z. C. Wu,Z. L. Ji,Y. Z. Chen,X. Chen

DOI: https://doi.org/10.2165/00822942-200605030-00001

2012-01-01

Applied Bioinformatics

Abstract:It has been demonstrated that numerous proteins interact with drugs or their metabolites. Knowledge of these proteins is necessary to understand the mechanisms of drug action and human response. Progress in modern genetics, molecular biology, biochemistry and pharmacology is generating a comprehensive mechanistic understanding of drug-target interaction on the molecular level. This is valuable for researchers and pharmaceutical companies in their efforts to improve the efficacy of existing drugs and to discover new ones. Most recently, the integration of a systems biology approach into drug discovery processes calls for more holistic knowledge and easily accessible resources of the proteins that are important in drug action and human response. We have reviewed many publicly accessible internet resources of these proteins, according to their roles in drug action and human response, such as therapeutic effect, adverse reaction, absorption, distribution, metabolism and excretion.
Towardcross-Platformelectronic Health Record-Drivenphenotyping Using Clinical Quality Language

Pascal S Brandt,Richard C Kiefer,Jennifer A Pacheco,Prakash Adekkanattu,Evan T Sholle,Faraz S Ahmad,Jie Xu,Zhenxing Xu,Jessica S Ancker,Fei Wang,Yuan Luo,Guoqian Jiang,Jyotishman Pathak,Luke V Rasmussen

DOI: https://doi.org/10.1002/lrh2.10233

2020-01-01

Learning Health Systems

Abstract:Introduction Electronic health record (EHR)-driven phenotyping is a critical first step in generating biomedical knowledge from EHR data. Despite recent progress, current phenotyping approaches are manual, time-consuming, error-prone, and platform-specific. This results in duplication of effort and highly variable results across systems and institutions, and is not scalable or portable. In this work, we investigate how the nascent Clinical Quality Language (CQL) can address these issues and enable high-throughput, cross-platform phenotyping. Methods We selected a clinically validated heart failure (HF) phenotype definition and translated it into CQL, then developed a CQL execution engine to integrate with the Observational Health Data Sciences and Informatics (OHDSI) platform. We executed the phenotype definition at two large academic medical centers, Northwestern Medicine and Weill Cornell Medicine, and conducted results verification (n = 100) to determine precision and recall. We additionally executed the same phenotype definition against two different data platforms, OHDSI and Fast Healthcare Interoperability Resources (FHIR), using the same underlying dataset and compared the results. Results CQL is expressive enough to represent the HF phenotype definition, including Boolean and aggregate operators, and temporal relationships between data elements. The language design also enabled the implementation of a custom execution engine with relative ease, and results verification at both sites revealed that precision and recall were both 100%. Cross-platform execution resulted in identical patient cohorts generated by both data platforms. Conclusions CQL supports the representation of arbitrarily complex phenotype definitions, and our execution engine implementation demonstrated cross-platform execution against two widely used clinical data platforms. The language thus has the potential to help address current limitations with portability in EHR-driven phenotyping and scale in learning health systems.
Characterizing the genetic architecture of drug response using gene-context interaction methods

Michal Sadowski,Mike Thompson,Joel Mefford,Tanushree Haldar,Akinyemi Oni-Orisan,Richard Border,Ali Pazokitoroudi,Julien F. Ayroles,Sriram Sankararaman,Andy Dahl,Noah Zaitlen

DOI: https://doi.org/10.1101/2024.03.29.24305093

2024-03-30

Abstract:Identifying the factors responsible for variability of treatment response is a central objective of clinical research. Specially designed pharmacogenomic studies have identified a handful of individual mutations modulating the effect of specific drugs. However, the extent to which drug response variability is driven by genetics is largely unknown, partly due to the small sample sizes of prospective pharmacogenomic trials. In this work, we develop a framework to study the genetic architecture of response to commonly prescribed drugs in large biobanks coupled with electronic health records. Our framework leverages concepts from gene-environment interaction testing, including novel interaction models at the level of genes, polygenic scores (PGS), and genome-wide heritability. We quantified the heritability of response to statins, metformin, warfarin, and methotrexate in 342,257 UK Biobank participants. Our results show that genetic variation modifies the primary effect of statins on LDL cholesterol (9% heritable) as well as its side effects on hemoglobin A1c and blood glucose (10% and 11% heritable, respectively). Next, we identified dozens of specific genes that modify drug response, which we then replicated in a retrospective pharmacogenomic study. Finally, we found that PGS accuracy varies up to 2-fold depending on treatment status, showing that the current approach of building PGS using mostly healthy individuals is likely to underperform in clinical contexts. Together, our results provide a framework for characterizing the genetic architecture of drug response using cross-sectional data.

Genetic and Genomic Medicine
Transcriptional Characterization of Resistance in Early Drug Response

Cole Ruoff,Allison Mitchell,Priya Mondal,Vishaka Gopalan,Michael Gottesman,Sridhar Hannenhalli

DOI: https://doi.org/10.1101/2024.07.05.602281

2024-07-10

Abstract:Therapeutic resistance is the leading cause of treatment failure and death from cancer. While resistance can be driven by genetic mutations, mounting evidence also points to an epigenetic basis of resistance. Much of this epigenetic, or non-genetic, resistance has been attributed to drug-resistant transcriptional cell states that are either induced by drug treatment or pre-exist in a fraction of cells selected by treatment. However, the extent to which long-term resistance is manifested in the early inherent cellular response to drugs is poorly understood, and which aspects, if any, of this early response to drug-induced transcriptional response are evolutionarily conserved properties of cells. To address these questions, we integrate datasets of long-term drug resistance and early drug response data across multiple cell lines with drug response and resistance data from bacteria and yeast. Our findings suggest that cancer cell states in both the drug-naive populations as well as in populations shortly after treatment share transcriptional properties with fully established resistant cell populations, and CRISPR-cas9 knockout of transcription factors predicted to regulate the resistant transcriptional programs result in inceased drug sensitivity. Furthermore, the resistance states manifested as early drug response are evolutionarily conserved. Finally, we show that early resistant states discriminate responders from non-responders across multiple human cancer trials.

Cancer Biology
CeDR Atlas: a knowledgebase of cellular drug response

Yin-Ying Wang,Hongen Kang,Tianyi Xu,Lili Hao,Yiming Bao,Peilin Jia

DOI: https://doi.org/10.1093/nar/gkab897

IF: 14.9

2021-10-11

Nucleic Acids Research

Abstract:Abstract Drug response to many diseases varies dramatically due to the complex genomics and functional features and contexts. Cellular diversity of human tissues, especially tumors, is one of the major contributing factors to the different drug response in different samples. With the accumulation of single-cell RNA sequencing (scRNA-seq) data, it is now possible to study the drug response to different treatments at the single cell resolution. Here, we present CeDR Atlas (available at https://ngdc.cncb.ac.cn/cedr), a knowledgebase reporting computational inference of cellular drug response for hundreds of cell types from various tissues. We took advantage of the high-throughput profiling of drug-induced gene expression available through the Connectivity Map resource (CMap) as well as hundreds of scRNA-seq data covering cells from a wide variety of organs/tissues, diseases, and conditions. Currently, CeDR maintains the results for more than 582 single cell data objects for human, mouse and cell lines, including about 140 phenotypes and 1250 tissue-cell combination types. All the results can be explored and searched by keywords for drugs, cell types, tissues, diseases, and signature genes. Overall, CeDR fine maps drug response at cellular resolution and sheds lights on the design of combinatorial treatments, drug resistance and even drug side effects.

biochemistry & molecular biology
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines

Wei Zhao,Jun Li,Mei-Ju M Chen,Yikai Luo,Zhenlin Ju,Nicole K Nesser,Katie Johnson-Camacho,Christopher T Boniface,Yancey Lawrence,Nupur T Pande,Michael A Davies,Meenhard Herlyn,Taru Muranen,Ioannis K Zervantonakis,Erika von Euw,Andre Schultz,Shwetha V Kumar,Anil Korkut,Paul T Spellman,Rehan Akbani,Dennis J Slamon,Joe W Gray,Joan S Brugge,Yiling Lu,Gordon B Mills,Han Liang,Mei-Ju M. Chen,Nicole K. Nesser,Christopher T. Boniface,Nupur T. Pande,Michael A. Davies,Ioannis K. Zervantonakis,Shwetha V. Kumar,Paul T. Spellman,Dennis J. Slamon,Joe W. Gray,Joan S. Brugge,Gordon B. Mills

DOI: https://doi.org/10.1016/j.ccell.2020.10.008

IF: 50.3

2020-12-01

Cancer Cell

Abstract:Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed expression profiles of ∼210 clinically relevant proteins in >12,000 cancer cell line samples in response to ∼170 drug compounds using reverse-phase protein arrays. We show that integrating perturbed protein response signals provides mechanistic insights into drug resistance, increases the predictive power for drug sensitivity, and helps identify effective drug combinations. We build a systematic map of "protein-drug" connectivity and develop a user-friendly data portal for community use. Our study provides a rich resource to investigate the behaviors of cancer cells and the dependencies of treatment responses, thereby enabling a broad range of biomedical applications.

oncology,cell biology
Promises and challenges in pharmacoepigenetics

Delaney A Smith,Marie C Sadler,Russ B Altman

DOI: https://doi.org/10.1017/pcm.2023.6

2023-02-09

Abstract:Pharmacogenetics, the study of how interindividual genetic differences affect drug response, does not explain all observed heritable variance in drug response. Epigenetic mechanisms, such as DNA methylation, and histone acetylation may account for some of the unexplained variances. Epigenetic mechanisms modulate gene expression and can be suitable drug targets and can impact the action of nonepigenetic drugs. Pharmacoepigenetics is the field that studies the relationship between epigenetic variability and drug response. Much of this research focuses on compounds targeting epigenetic mechanisms, called epigenetic drugs, which are used to treat cancers, immune disorders, and other diseases. Several studies also suggest an epigenetic role in classical drug response; however, we know little about this area. The amount of information correlating epigenetic biomarkers to molecular datasets has recently expanded due to technological advances, and novel computational approaches have emerged to better identify and predict epigenetic interactions. We propose that the relationship between epigenetics and classical drug response may be examined using data already available by (1) finding regions of epigenetic variance, (2) pinpointing key epigenetic biomarkers within these regions, and (3) mapping these biomarkers to a drug-response phenotype. This approach expands on existing knowledge to generate putative pharmacoepigenetic relationships, which can be tested experimentally. Epigenetic modifications are involved in disease and drug response. Therefore, understanding how epigenetic drivers impact the response to classical drugs is important for improving drug design and administration to better treat disease.
CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

Zhongyang Liu,Jiale Liu,Xinyue Liu,Xun Wang,Qiaosheng Xie,Xinlei Zhang,Xiangya Kong,Mengqi He,Yuting Yang,Xinru Deng,Lele Yang,Yaning Qi,Jiajun Li,Yuan Liu,Liying Yuan,Lihong Diao,Fuchu He,Dong Li

DOI: https://doi.org/10.1093/nar/gkab860

IF: 14.9

2021-09-27

Nucleic Acids Research

Abstract:Abstract To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportunities for exploring molecular determinants of drug response, but meanwhile pose challenges for data management, integration, and reuse. Here we present the Cancer Treatment Response gene signature DataBase (CTR-DB, http://ctrdb.ncpsb.org.cn/), a unique database for basic and clinical researchers to access, integrate, and reuse clinical transcriptomes with cancer drug response. CTR-DB has collected and uniformly reprocessed 83 patient-derived pre-treatment transcriptomic source datasets with manually curated cancer drug response information, involving 28 histological cancer types, 123 drugs, and 5139 patient samples. These data are browsable, searchable, and downloadable. Moreover, CTR-DB supports single-dataset exploration (including differential gene expression, receiver operating characteristic curve, functional enrichment, sensitizing drug search, and tumor microenvironment analyses), and multiple-dataset combination and comparison, as well as biomarker validation function, which provide insights into the drug resistance mechanism, predictive biomarker discovery and validation, drug combination, and resistance mechanism heterogeneity.

biochemistry & molecular biology
Building a Pharmacogenomics Knowledge Model Toward Precision Medicine: Case Study in Melanoma

Hongyu Kang,Jiao Li,Meng Wu,Liu Shen,Li Hou

DOI: https://doi.org/10.2196/20291

2020-10-21

Abstract:Background: Many drugs do not work the same way for everyone owing to distinctions in their genes. Pharmacogenomics (PGx) aims to understand how genetic variants influence drug efficacy and toxicity. It is often considered one of the most actionable areas of the personalized medicine paradigm. However, little prior work has included in-depth explorations and descriptions of drug usage, dosage adjustment, and so on. Objective: We present a pharmacogenomics knowledge model to discover the hidden relationships between PGx entities such as drugs, genes, and diseases, especially details in precise medication. Methods: PGx open data such as DrugBank and RxNorm were integrated in this study, as well as drug labels published by the US Food and Drug Administration. We annotated 190 drug labels manually for entities and relationships. Based on the annotation results, we trained 3 different natural language processing models to complete entity recognition. Finally, the pharmacogenomics knowledge model was described in detail. Results: In entity recognition tasks, the Bidirectional Encoder Representations from Transformers-conditional random field model achieved better performance with micro-F1 score of 85.12%. The pharmacogenomics knowledge model in our study included 5 semantic types: drug, gene, disease, precise medication (population, daily dose, dose form, frequency, etc), and adverse reaction. Meanwhile, 26 semantic relationships were defined in detail. Taking melanoma caused by a BRAF gene mutation into consideration, the pharmacogenomics knowledge model covered 7 related drugs and 4846 triples were established in this case. All the corpora, relationship definitions, and triples were made publically available. Conclusions: We highlighted the pharmacogenomics knowledge model as a scalable framework for clinicians and clinical pharmacists to adjust drug dosage according to patient-specific genetic variation, and for pharmaceutical researchers to develop new drugs. In the future, a series of other antitumor drugs and automatic relation extractions will be taken into consideration to further enhance our framework with more PGx linked data.
Virtual Pharmacist: A Platform for Pharmacogenomics

Ronghai Cheng,Ross Ka-Kit Leung,Yao Chen,Yidan Pan,Yin Tong,Zhoufang Li,Luwen Ning,Xuefeng B. Ling,Jiankui He

DOI: https://doi.org/10.1371/journal.pone.0141105

IF: 3.7

2015-10-23

PLoS ONE

Abstract:We present Virtual Pharmacist, a web-based platform that takes common types of high-throughput data, namely microarray SNP genotyping data, FASTQ and Variant Call Format (VCF) files as inputs, and reports potential drug responses in terms of efficacy, dosage and toxicity at one glance. Batch submission facilitates multivariate analysis or data mining of targeted groups. Individual analysis consists of a report that is readily comprehensible to patients and practioners who have basic knowledge in pharmacology, a table that summarizes variants and potential affected drug response according to the US Food and Drug Administration pharmacogenomic biomarker labeled drug list and PharmGKB, and visualization of a gene-drug-target network. Group analysis provides the distribution of the variants and potential affected drug response of a target group, a sample-gene variant count table, and a sample-drug count table. Our analysis of genomes from the 1000 Genome Project underlines the potentially differential drug responses among different human populations. Even within the same population, the findings from Watson's genome highlight the importance of personalized medicine. Virtual Pharmacist can be accessed freely at http://www.sustc-genome.org.cn/vp or installed as a local web server. The codes and documentation are available at the GitHub repository (https://github.com/VirtualPharmacist/vp). Administrators can download the source codes to customize access settings for further development.

multidisciplinary sciences
Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

Zetian Zheng,Lei Huang,Fuzhou Wang,Linjing Liu,Jixiang Yu,Weidun Xie,Xingjian Chen,Xiangtao Li,Ka-Chun Wong

DOI: https://doi.org/10.1101/2024.12.04.626700

2024-12-07

Abstract:Cancer cell lines are the most common in-vitro models for the evaluation of anti-cancer drug sensitivities. Past studies have been conducted to decipher and characterize the pharmacogenomic feature of cell lines based on other omics data, such as genomic mutation data and whole-genome RNA sequencing (RNA-seq) profiles. In particular, proteomic data is also an essential component for the characterization of tumours. However, different from RNA-seq datasets rich in numerous transcriptome profiles of cancer cell lines and cell viability assay of drug responses, the pharmacogenomic protein quantifications are relatively scarce. With the availability of the recently enriched proteomic dataset ProCan-DepMapSanger, we systematically evaluated the interplays among genomic mutations, transcription, and protein expressions across cancer cell lines. In general, blood cancers have higher RNA-protein correlations than those in solid cancers. The differential expression analysis on protein data helped identify more expressional and functional impact of genomic mutations of cancer genes. We also integrated the proteomic map with drug molecular chemical features to construct a bi-modal machine learning model to infer the drug sensitivities of cancer cell lines. Our results demonstrated that protein quantifications can lead to better drug response prediction performance than the model trained on transcriptome profiles. In addition, integrating protein data with drug chemical features, represented as molecular graphs and learned by Graph Neural Network, outperformed the state-of-the-art model DeepOmicNet for drug response prediction in proteomics.

Bioinformatics
Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

Yue Xu,Jie Zheng,Zhaoqing Cai,Wang Li,Jens Köhler,Yao Dai,Xiaojie Cheng,Tao Wu,Fan Zhang,Haiyun Wang

DOI: https://doi.org/10.3389/fcell.2021.773101

IF: 5.5

2021-11-12

Frontiers in Cell and Developmental Biology

Abstract:Cancers that are histologically defined as the same type of cancer often need a distinct therapy based on underlying heterogeneity; likewise, histologically disparate cancers can require similar treatment approaches due to intrinsic similarities. A comprehensive analysis integrated with drug response data and molecular alterations, particularly to reveal therapeutic concordance mechanisms across histologically disparate tumor subtypes, has not yet been fully exploited. In this study, we integrated pharmacological, genomic, and transcriptomic profiling data provided from the Cancer Genome Project (CGP) in a systematic in silico investigation of the pharmacological subtypes of cancers and the intrinsic concordance of molecular mechanisms leading to similar therapeutic responses across histologically disparate tumor subtypes. We further developed a novel approach to redefine cell-to-cell similarity and drug-to-drug similarity from the therapeutic concordance, providing a new point of view to study cancer heterogeneity. This study demonstrates how pharmacological and omics data can be used to systematically classify cancers in terms of response to various compounds and provides us with a purely therapy-oriented perspective to view tumor classifications independent of histology subtypes. The knowledge of pharmacological subtypes of 367 drugs are available via our website ( http://www.hywanglab.cn/dtdb/ ), providing the resources for precision medicine in the perspective of therapeutic response-based re-classification of tumor.

cell biology,developmental biology
PhenCards: a data resource linking human phenotype information to biomedical knowledge

James M. Havrilla,Cong Liu,Xiangchen Dong,Chunhua Weng,Kai Wang

DOI: https://doi.org/10.1186/s13073-021-00909-8

IF: 15.266

2021-05-25

Genome Medicine

Abstract:Abstract We present PhenCards ( https://phencards.org ), a database and web server intended as a one-stop shop for previously disconnected biomedical knowledge related to human clinical phenotypes. Users can query human phenotype terms or clinical notes. PhenCards obtains relevant disease/phenotype prevalence and co-occurrence, drug, procedural, pathway, literature, grant, and collaborator data. PhenCards recommends the most probable genetic diseases and candidate genes based on phenotype terms from clinical notes. PhenCards facilitates exploration of phenotype, e.g., which drugs cause or are prescribed for patient symptoms, which genes likely cause specific symptoms, and which comorbidities co-occur with phenotypes.

genetics & heredity
GEAR: A database of G enomic E lements A ssociated with drug R esistance

Yin-Ying Wang,Wei-Hua Chen,Pei-Pei Xiao,Wen-Bin Xie,Qibin Luo,Peer Bork,Xing-Ming Zhao

DOI: https://doi.org/10.1038/srep44085

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Drug resistance is becoming a serious problem that leads to the failure of standard treatments, which is generally developed because of genetic mutations of certain molecules. Here, we present GEAR (A database of G enomic E lements A ssociated with drug R esistance) that aims to provide comprehensive information about genomic elements (including genes, single-nucleotide polymorphisms and microRNAs) that are responsible for drug resistance. Right now, GEAR contains 1631 associations between 201 human drugs and 758 genes, 106 associations between 29 human drugs and 66 miRNAs, and 44 associations between 17 human drugs and 22 SNPs. These relationships are firstly extracted from primary literature with text mining and then manually curated. The drug resistome deposited in GEAR provides insights into the genetic factors underlying drug resistance. In addition, new indications and potential drug combinations can be identified based on the resistome. The GEAR database can be freely accessed through http://gear.comp-sysbio.org .
Predicting Drug Responses by Propagating Interactions through Text-Enhanced Drug-Gene Networks

Shiyin Wang

DOI: https://doi.org/10.48550/arXiv.1906.08089

2019-06-19

Social and Information Networks

Abstract:Personalized drug response has received public awareness in recent years. How to combine gene test result and drug sensitivity records is regarded as essential in the real-world implementation. Research articles are good sources to train machine predicting, inference, reasoning, etc. In this project, we combine the patterns mined from biological research articles and categorical data to construct a drug-gene interaction network. Then we use the cell line experimental records on gene and drug sensitivity to estimate the edge embeddings in the network. Our model provides white-box explainable predictions of drug response based on gene records, which achieves 94.74% accuracy in binary drug sensitivity prediction task.

Drug Response Phenotype Terms

Leveraging a pharmacogenomics knowledgebase to formulate a drug response phenotype terminology for genomic medicine

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Internet Resources Related to Drug Action and Human Response: A Review

Towardcross-Platformelectronic Health Record-Drivenphenotyping Using Clinical Quality Language

Characterizing the genetic architecture of drug response using gene-context interaction methods

Transcriptional Characterization of Resistance in Early Drug Response

CeDR Atlas: a knowledgebase of cellular drug response

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines

Promises and challenges in pharmacoepigenetics

CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

Building a Pharmacogenomics Knowledge Model Toward Precision Medicine: Case Study in Melanoma

Virtual Pharmacist: A Platform for Pharmacogenomics

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers

PhenCards: a data resource linking human phenotype information to biomedical knowledge

GEAR: A database of G enomic E lements A ssociated with drug R esistance

Predicting Drug Responses by Propagating Interactions through Text-Enhanced Drug-Gene Networks